Olaparib continues to show positive results in advanced ovarian cancer - 7 year data
Prof Paul DiSilvestro, speaks to ecancer about his Phase III SOLO1/GOG-3004 trial which studied the overall survival at 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib.ย
Patients who were in response to first-line platinum-based chemotherapy received maintenance olaparib tablets 300 mg bid or pbo for up to 2 years or until progression. A descriptive analysis of OS, a secondary endpoint, was performed 7y after the last patient was randomised; prespecified final analysis of OS is planned at 60% data maturity.
The results showed that 2 years of maintenance olaparib provided a clinically meaningful improvement in OS over placebo in patients with newly diagnosed advanced OC and a BRCAm.
These data provide the longest follow up for any PARP inhibitor in this setting and support use of maintenance olaparib to achieve long-term remission and enhance the potential for cure.
No comments found